Back to comparisons

Comparison

Modafinil vs Kratom (Mitragyna speciosa)

FieldModafinilKratom (Mitragyna speciosa)
Categorystimulantstimulant
Dose range100–200mg1000–8000mg
Half-life14h
Onset45min
EvidenceEVIDENCEAEVIDENCEC
Safety●●●○○●●○○○
Legal (US)USSchedule IVUSUnscheduled
PubMed refs3200800

The comparison in plain English

Auto-generated from data

Modafinil and Kratom (Mitragyna speciosa) are both in the stimulant category respectively. Modafinil A eugeroic — a wakefulness-promoting compound — originally developed for narcolepsy. Kratom (Mitragyna speciosa) Southeast Asian tree (Mitragyna speciosa) with opioid-like and stimulant effects.

Bottom line

Modafinil (evidence A, safety 3/5) has a weaker evidence base than Kratom (Mitragyna speciosa) (evidence C, safety 2/5). Modafinil has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.

Choose Modafinil if

Modafinil is the better fit when your goal aligns with its mechanism (Inhibits dopamine reuptake via the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex) and the dose range (100–200mg) suits your protocol. Half-life is 14h.

Choose Kratom (Mitragyna speciosa) if

Kratom (Mitragyna speciosa) is the better fit when your goal aligns with its mechanism (Primary alkaloid mitragynine is a partial agonist at mu-opioid receptors with biased signaling — produces analgesia and mood elevation with less respiratory depression than classical opioids) and the dose range (1000–8000mg) suits your protocol. Half-life is —h.

Build a stack with bothOpen builder →
Check interactionsOpen checker →